trending Market Intelligence /marketintelligence/en/news-insights/trending/-9MP_Rk9vPm3bzlDFX_kMg2 content esgSubNav
In This List

Novelion Therapeutics to dissolve Jan. 16

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Novelion Therapeutics to dissolve Jan. 16

Novelion Therapeutics Inc. said the company will shut down Jan. 16 after the Supreme Court of British Columbia granted the orders for voluntary liquidation.

Alvarez & Marsal Canada Inc. will be appointed as the liquidator on the date, and concurrently, Michael Price, executive vice president and CFO, will resign. Price is the company's sole executive officer.

In addition, Price and two other directors, Suzanne Bruhn and Stephen Sabba, will resign from the board of the Vancouver, British Columbia-based company.

After the effective date, the transfer agent of Novelion's common shares will discontinue recording share transfers.